Market revenue in 2021 | USD 262.1 million |
Market revenue in 2028 | USD 552.5 million |
Growth rate | 11.2% (CAGR from 2021 to 2028) |
Largest segment | Commercialized |
Fastest growing segment | Commercialized |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Research, Commercialized |
Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 56.24% in 2021. Horizon Databook has segmented the UK t-cell therapy market based on research, commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
In October 2018, Kymriah and Yescarta were approved by the NHS for the treatment of blood cancer. In addition, NHS issued recommendations to select hospitals offering treatment for monitoring side effects and plan post-administration supportive care. After approval, it was announced that NHS would fund Kymriah for the treatment of ALL through the Cancer Drugs Fund (CDF).
Initially, the draft guidance for both approved drugs was rejected due to lack of any comparative data against chemotherapy. However, Yescarta was the first T-cell therapy to be approved owing to positive recommendation from NICE. Furthermore, Gilead’s agreement with NHS enabled the entry of the drug into the CDF, facilitating commercialization.
Horizon Databook provides a detailed overview of country-level data and insights on the UK t-cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into UK t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account